|Description||Infections Disease Diagnostic Agents|
|Series C, 1/08 |
Iowa Capital Management
Ames Seed Capital
|Series D, 7/09 ||$7.5M|
NewLink Genetics is a biopharmaceutical company applying innovative approaches to create new therapeutic and diagnostic agents for patients with cancer and infectious diseases. The senior personnel of NewLink have extensive backgrounds in cancer biology, immunology, infectious disease & molecular genetics with a decade of professional collaboration amongst the principals of the company preceding the start of operations at NewLink in 1999. The majority of these critical personnel have been trained at prominent International institutions such as Stanford, the National Cancer Institute, UCSF, and the National Human Genome Research Institute.